This clinical-stage oncology biotechnology company is focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of haematological cancers and solid tumours.
This clinical-stage oncology biotechnology company is focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of haematological cancers and solid tumours.